[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597307":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":63,"collaborators":25,"id":65,"slug":25,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients will undergo a 68Ga-PSMA-CYC PET\u002FCT 、68Ga-PSMA-617 or 68Ga-PSMA-11 PET\u002FCT","ACTIVE_COMPARATOR","Prostate Patients received 68Ga-PSMA-CYC 、68Ga-PSMA-617 or 68Ga-PSMA-11 PET\u002FCT imaging within one week. Tracer doses of 68Ga-PSMA-CYC、68Ga-PSMA-617 or 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET\u002FCT",[13],"Drug: 68Ga-PSMA-CYC",{"label":15,"type":16,"description":17,"interventionNames":18},"68Ga-PSMA-CYC","EXPERIMENTAL","Experimental: dynamic PET scans PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 150 minutes after injection",[19],"Drug: CYC",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET\u002FCT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET\u002FCT scan, with the time interval between the two scans not exceeding one week.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"CYC","The dose will be 3-4mCi given intravenously.",[15],[31],{"name":32,"affiliation":5,"role":33},"Weibing Miao, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","059187981618","miaoweibing@126.com",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Jie Zang, MD","15901495106","15901495106@163.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":53,"coordinates":54},"Point",[55,56],119.30611,26.06139,{"lat":56,"lon":55},[59,62],{"name":60,"role":36,"phone":61,"phoneExt":25,"email":38},"weibing miao, MD","+86-0591-87981618",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},{"type":64,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100597307",false,"NCT07056790","Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer","Inclusion Criteria:\n\n* confirmed treated or untreated prostate cancer patients;\n* signed written consent.\n\nExclusion Criteria:\n\n* known allergy against PSMA;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.","MALE","18 Years","80 Years",{"count":74,"type":75},40,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET\u002FCT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.",[82],"Prostate CA",[84,85],"psma","prostate cancer","2025-06-30",{"date":88,"type":89},"2025-07-09","ACTUAL",{"date":91,"type":89},"2025-05-15",{"date":93,"type":75},"2027-05",{"name":5,"class":6},1]